From now on, the widespread use of newly available non-invasive diagnostic biomarkers (e.g. plasma oxysterols or lysosphingolipids [3, 30]) will likely identify NP-C patients with no VSGP at diagnosis, as we have begun to observe. This evidence concerns the gene SPON1 and nasopharyngeal carcinoma.